Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
1997-2-27
pubmed:abstractText
Ciprofloxacin-resistant mutants of Streptococcus pneumoniae 7785 were generated by stepwise selection at increasing drug concentrations. Sequence analysis of PCR products from the strains was used to examine the quinolone resistance-determining regions of the GyrA and GyrB proteins of DNA gyrase and the analogous regions of the ParC and ParE subunits of DNA topoisomerase IV. First-step mutants exhibiting low-level resistance had no detectable changes in their topoisomerase quinolone resistance-determining regions, suggesting altered permeation or another novel resistance mechanism. Nine of 10 second-step mutants exhibited an alteration in ParC at Ser-79 to Tyr or Phe or at Ala-84 to Thr. Third- and fourth-step mutants displaying high-level ciprofloxacin resistance were found to have, in addition to the ParC alteration, a change in GyrA at residues equivalent to Escherichia coli GyrA resistance hot spots Ser-83 and Asp-87 or in GyrB at Asp-435 to Asn, equivalent to E. coli Asp-426, part of a highly conserved EGDSA motif in GyrB. No ParE changes were observed. Complementary analysis of two S. pneumoniae clinical isolates displaying low-level resistance to ciprofloxacin revealed a ParC change at Ser-79 to Phe or Arg-95 to Cys but no changes in GyrA, GyrB, or ParE. A highly resistant isolate, in addition to a ParC mutation, had a GyrA alteration at the residue equivalent to E. coli Asp-87. Thus, in both laboratory strains and clinical isolates, ParC mutations preceded those in GyrA, suggesting that topoisomerase IV is a primary topoisomerase target and gyrase is a secondary target for ciprofloxacin in S. pneumoniae.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/8891138-1311298, http://linkedlifedata.com/resource/pubmed/commentcorrection/8891138-1330320, http://linkedlifedata.com/resource/pubmed/commentcorrection/8891138-1656869, http://linkedlifedata.com/resource/pubmed/commentcorrection/8891138-1662027, http://linkedlifedata.com/resource/pubmed/commentcorrection/8891138-1850972, http://linkedlifedata.com/resource/pubmed/commentcorrection/8891138-186775, http://linkedlifedata.com/resource/pubmed/commentcorrection/8891138-2168148, http://linkedlifedata.com/resource/pubmed/commentcorrection/8891138-2170028, http://linkedlifedata.com/resource/pubmed/commentcorrection/8891138-2174864, http://linkedlifedata.com/resource/pubmed/commentcorrection/8891138-2174869, http://linkedlifedata.com/resource/pubmed/commentcorrection/8891138-2187594, http://linkedlifedata.com/resource/pubmed/commentcorrection/8891138-2548439, http://linkedlifedata.com/resource/pubmed/commentcorrection/8891138-271968, http://linkedlifedata.com/resource/pubmed/commentcorrection/8891138-2817852, http://linkedlifedata.com/resource/pubmed/commentcorrection/8891138-3020376, http://linkedlifedata.com/resource/pubmed/commentcorrection/8891138-3031051, http://linkedlifedata.com/resource/pubmed/commentcorrection/8891138-337300, http://linkedlifedata.com/resource/pubmed/commentcorrection/8891138-6246508, http://linkedlifedata.com/resource/pubmed/commentcorrection/8891138-6270661, http://linkedlifedata.com/resource/pubmed/commentcorrection/8891138-7492103, http://linkedlifedata.com/resource/pubmed/commentcorrection/8891138-7811012, http://linkedlifedata.com/resource/pubmed/commentcorrection/8891138-7811024, http://linkedlifedata.com/resource/pubmed/commentcorrection/8891138-7830580, http://linkedlifedata.com/resource/pubmed/commentcorrection/8891138-7872758, http://linkedlifedata.com/resource/pubmed/commentcorrection/8891138-7997176, http://linkedlifedata.com/resource/pubmed/commentcorrection/8891138-8192436, http://linkedlifedata.com/resource/pubmed/commentcorrection/8891138-8381633, http://linkedlifedata.com/resource/pubmed/commentcorrection/8891138-8388200, http://linkedlifedata.com/resource/pubmed/commentcorrection/8891138-8524852, http://linkedlifedata.com/resource/pubmed/commentcorrection/8891138-8538787, http://linkedlifedata.com/resource/pubmed/commentcorrection/8891138-8549285, http://linkedlifedata.com/resource/pubmed/commentcorrection/8891138-8549407, http://linkedlifedata.com/resource/pubmed/commentcorrection/8891138-8723458, http://linkedlifedata.com/resource/pubmed/commentcorrection/8891138-8723480, http://linkedlifedata.com/resource/pubmed/commentcorrection/8891138-8763932, http://linkedlifedata.com/resource/pubmed/commentcorrection/8891138-8849244, http://linkedlifedata.com/resource/pubmed/commentcorrection/8891138-8851598
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0066-4804
pubmed:author
pubmed:issnType
Print
pubmed:volume
40
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2321-6
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed:year
1996
pubmed:articleTitle
Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae.
pubmed:affiliation
Department of Cellular and Molecular Sciences, St. George's Hospital Medical School, University of London, United Kingdom.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't